AstraZeneca's respiratory tract infection treatment gets prior status from European Medicines Agency

Writer, Stock Market Wire
Tuesday, February 5, 2019 - 07:52

AstraZeneca said Tuesday its treatment for lower respiratory tract infection caused by the respiratory syncytial virus had received priority status from the European Medicines Agency.

The PRIME (PRIority MEdicines) initiative offered proactive and enhanced support to developers of promising medicines to optimise development plans and accelerate evaluation so these medicines can reach patients faster.

This was the first EMA PRIME eligibility that AstraZeneca had received since the programme's initiation in 2016.

'We are excited to receive PRIME eligibility for MEDI8897, our next-generation monoclonal antibody targeting respiratory syncytial virus in infants. We will work closely with the European Medicines Agency to optimise our development plan and help us bring MEDI8897 to patients as quickly as possible,' said Mene Pangalos, Executive Vice-President, R&D BioPharmaceuticals.


Related content

Astrazeneca's lung disease treatment granted orphan drug status in US

Astrazeneca said its potential new treatment for lung disease had been granted orphan drug designation by the US Food and Drug Administration.

The company's 'potential'...

Mon, 18/03/2019 - 07:42


Broker Forecast - Goldman Sachs issues a broker note on AstraZeneca PLC

Goldman Sachs today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5000p (from 4080p).

Broker Forecasts data provided...

Tue, 12/03/2019 - 13:10


AstraZeneca, Merck breast cancer treatment gets EU regulatory nod

AstraZeneca and Merck said they had a received a positive opinion from EU regulators on a treatment for breast cancer.

The Committee for Medicinal Products...

Fri, 01/03/2019 - 15:11


Aston Martin and Howden Joinery

“Markets around the world take a step back amid disappointment over Donald Trump’s failure to reach a deal with North Korea and weak manufacturing data...

Thu, 28/02/2019 - 10:06


AstraZeneca heart treatment shown to be effective during trial

AstraZeneca said a trial of a treatment for heart problems showed a reduction in major adverse cardiovascular events.

The company's heart drug Themis taken together...

Mon, 25/02/2019 - 16:16